Skip to content

Enterprise value at other companies

HRO
HarrowHROW
$1.53B+13.8%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$452.74M+5.3%
XER
Xeris Biopharma Holdings, Inc.XERS
$1.15B+8.7%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.83B-51.1%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$1.72B+5.8%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$3.74B+21.5%

Other financials

Income statement

See full
Revenue$24.3M+40.4%
Gross profit$14.7M+49.4%
Operating income$2.4M+614%
Net income$1.6M+199%
EPS (diluted)$0.05+183%

Balance sheet

See full
Cash & equivalents$19.7M+12.9%
Total debt$31.3M+3.7%
Total equity$30.6M+25.2%
Total assets$97.7M+16.3%

Cash flow

See full
Operating cash flow$7.4M+254%
CapEx$75.0K
Free cash flow$7.3M+251%

Valuation

See full
Market cap$930.79M+156%
P/S10.7×+3.2×

Profitability

See full
Gross margin54.8%-3.7pp
Operating margin-15.1%
Net margin-9.5%-2.7pp
FCF margin17.1%

Returns & leverage

See full
Return on equity-34.2%+0.9pp
Debt / equity-0.2×
Current ratio1.2×-0.8×

Where this comes from

Calculated from Eton Pharmaceuticals, Inc.’s reported figures.

The official record: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eton Pharmaceuticals, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Eton Pharmaceuticals, Inc.'s enterprise value?
Eton Pharmaceuticals, Inc. (ETON) reported enterprise value of $684.98M in Q1 2026.
How has Eton Pharmaceuticals, Inc.'s enterprise value changed year-over-year?
Eton Pharmaceuticals, Inc.'s enterprise value increased by 89.8% year-over-year, from $360.83M to $684.98M.
What is the long-term trend for Eton Pharmaceuticals, Inc.'s enterprise value?
Over 5 years (2020 to 2025), Eton Pharmaceuticals, Inc.'s enterprise value has grown at a 19.7% compound annual growth rate (CAGR), from $186.33M to $458.63M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.